POLYCYSTIC OVARY SYNDROME: PATHOGENESIS, TREATMENT AND SECONDARY ASSOCIATED DISEASES

POLYCYSTIC OVARY SYNDROME: PATHOGENESIS, TREATMENT AND SECONDARY ASSOCIATED DISEASES

  • Abhishek Soni Abhilashi University
  • Shivali Singla Himalayan Institute of Pharmacy, Kala-Amb, H.P. India
  • Sachin Goyal School of Pharmacy, Abhilashi University, Chail Chowk, Mandi (H.P), India

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. It is characterized by hyperandrogenism, polycystic ovaries, and chronic anovulation along with insulin resistance, hyperinsulinemia, abdominal obesity, hypertension, and dyslipidemia as frequent metabolic traits (metabolic syndrome) that culminate in serious long-term consequences such as type 2 diabetes mellitus, endometrial hyperplasia, and coronary artery disease. It is one of the most common causes of anovulatory infertility. A complete understanding of the underlying Pathophysiology of PCOS is still lacking. Because of the heterogeneity of this disorder, there are most likely multiple underlying pathophysiologic mechanisms. Pathogenesis of PCOS is explaining as alteration in gonadotropin-releasing hormone secretion results in increased luteinizing hormone (LH) secretion. An alteration in insulin secretion and insulin action results in hyperinsulinemia and insulin resistance. A defect in androgen synthesis that results in increased ovarian androgen production.Treatment of PCOS include maintaining a normal endometrium, antagonizing the actions of androgens on target tissues, reducing insulin resistance (when present), and correcting anovulation. Women with polycystic ovary syndrome (PCOS) are at higher risk for several other health conditions as Insulin Resistance, Metabolic Syndrome, Type 2 Diabetes, Obesity, Heart Disease and High Blood Pressure (Cardiovascular Disease)


 

Keywords: Polycystic ovary syndrome, luteinizing hormone, hyperandrogenism, Anovulation

Downloads

Download data is not yet available.

Author Biographies

Shivali Singla, Himalayan Institute of Pharmacy, Kala-Amb, H.P. India

Himalayan Institute of Pharmacy, Kala-Amb, H.P. India

Sachin Goyal, School of Pharmacy, Abhilashi University, Chail Chowk, Mandi (H.P), India

School of Pharmacy, Abhilashi University, Chail Chowk, Mandi (H.P), India

References

1. Gautam N. Allahbadia, Rubina Merchant: Polycystic Ovary Syndrome in the Indian Subcontinent, seminars in reproductive medicine. 2008; 26(1):22-34.
2. Saini Neetu, Sodhi Rupinder Kaur, Bajaj Lotika, Pandey Ravi Shankar, Jain Upendra Kumar , Katare Om Prakash, Madan Jitender: Colloids and Surfaces B: Biointerfaces 2016; 144:161–169
3. Franks S : Polycystic ovary syndrome. N Engl J Med 1995; 333:853– 61.
4. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr : Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:165-72.
5. Mcknight E: The prevalence of “hirsutism” in young women. Lancet. 1964; 1:410–3.
6. Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 2:1440–7.
7. Gruber DM, Berger UE, Sator MO, Horak F, Huber JC: Computerized assessment of facial hair growth. Fertil Steril. 1999; 72:737–9.
8. Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996; 275:1571-1576.
9. Ehrmann DA. Medical progress: Polycystic ovary syndrome. J Engl J Med 2005; 352:1223–36.
10. Tsilchorozidou T, Overton C, Conway GS: The Pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60:1–17.
11. Carmina E: Diagnosing PCOS in women who menstruat regularly. Contemp Obstet Gynecol 2003; 7:53-64.
12. Hill KM.: Update The pathogenesis and treatment of PCOS. Nurse Pract 2003; 28:8-25.
13. Ajayi R, Ogunmokun A: The importance of diagnosing polycystic ovary syndrome. In: Allahbadia GN, Agrawal R, eds. Polycystic Ovary Syndrome. Kent, UK: Anshan Publishers; 2006:38–45
14. Hashim H. A : Management of women with Clomifene Citrate resistant Polycystic Ovary Syndrome –An evidence based approach, Polycystic Ovary Syndrome, Dr. Srabani Mukherjee (Ed.), ISBN:978-953-51-0094-2
15. Stener-Victorin E, Waldenström U, Tägnfors U, Lundeberg T, Lindstedt G, Janson PO: Effects of electro-acupuncture on Anovulation in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2000; 79(3):180–188.
16. Swati C, Kumari M.S : An open Randomised control study to evaluate the combined effect of shodhna followed by sharmana chiktsa over polycystic ovarian syndrome, Int. J. Res. Ayurveda Pharm. 2015; 6(5).
17. Ehrmann D et al: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(1):48-53
18. Meyer C et al: Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005; 90(10):5711-6
19. McCartney CR, Marshall JC: Polycystic Ovary Syndrome. N Engl J Med 2016;375:54-64
20. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S: Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review, Published by 398-RBM Online , UK, 2009: 398-405
Statistics
30 Views | 77 Downloads
How to Cite
Soni, A., Singla, S., & Goyal, S. (2018). POLYCYSTIC OVARY SYNDROME: PATHOGENESIS, TREATMENT AND SECONDARY ASSOCIATED DISEASES. Journal of Drug Delivery and Therapeutics, 8(5), 107-112. https://doi.org/10.22270/jddt.v8i5.1892